Your browser doesn't support javascript.
Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia.
Alshukairi, Abeer N; Aldabbagh, Yasser; Adroub, Sabir A; Mourier, Tobias; Abumelha, Khalid Y; Albishi, Ghadeer E; Alraddadi, Basem M; Al Hroub, Mohammad K; El-Saed, Aiman; Ibrahim, Suzan M Nagash; Al Musawa, Mohammed; Almasari, Ahlam; Habahab, Wael T; Alhamlan, Fatimah S; Al-Omari, Awad; Pain, Arnab; Dada, Ashraf.
  • Alshukairi AN; Department of Medicine, King Faisal Specialist Hospital and Research Center, King Faisal Specialist Hospital and Research Center, PO BOX 40047, Jeddah, 21499, Kingdom of Saudi Arabia. abeer.alshukairi@gmail.com.
  • Aldabbagh Y; College of Medicine, AlFaisal University, Riyadh, Kingdom of Saudi Arabia. abeer.alshukairi@gmail.com.
  • Adroub SA; Department of Medicine, King Faisal Specialist Hospital and Research Center, King Faisal Specialist Hospital and Research Center, PO BOX 40047, Jeddah, 21499, Kingdom of Saudi Arabia.
  • Mourier T; Department of Medicine, Al-Moosa Specialist Hospital, Al-Ahsa, Kingdom of Saudi Arabia.
  • Abumelha KY; Pathogen Genomics Group, Bioscience Program, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia.
  • Albishi GE; Pathogen Genomics Group, Bioscience Program, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia.
  • Alraddadi BM; Department of Medicine, King Faisal Specialist Hospital and Research Center, King Faisal Specialist Hospital and Research Center, PO BOX 40047, Jeddah, 21499, Kingdom of Saudi Arabia.
  • Al Hroub MK; Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
  • El-Saed A; Department of Medicine, King Faisal Specialist Hospital and Research Center, King Faisal Specialist Hospital and Research Center, PO BOX 40047, Jeddah, 21499, Kingdom of Saudi Arabia.
  • Ibrahim SMN; College of Medicine, AlFaisal University, Riyadh, Kingdom of Saudi Arabia.
  • Al Musawa M; Department of Infection Control and Hospital Epidemiology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
  • Almasari A; Department of Infection Prevention and Control, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
  • Habahab WT; Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
  • Alhamlan FS; Department of Medical and Critical Care Pharmacy, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
  • Al-Omari A; Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
  • Pain A; Department of Medicine, King Faisal Specialist Hospital and Research Center, King Faisal Specialist Hospital and Research Center, PO BOX 40047, Jeddah, 21499, Kingdom of Saudi Arabia.
  • Dada A; Department of Infection and Immunity, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
J Epidemiol Glob Health ; 13(1): 47-54, 2023 03.
Article in English | MEDLINE | ID: covidwho-2175642
ABSTRACT
The outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality of transplant recipients. We reviewed the results of SARS-CoV-2 whole genome sequence of random isolates collected from 29 December 2021 until 17 May 2022 in King Faisal Specialist Hospital and Research center, Jeddah (KFSHRC-J), Saudi Arabia performed as hospital genomic surveillance program for COVID-19 variants. We included 25 transplant patients infected with confirmed Omicron variants.17 (68%) and 8 (32%) patients had Omicron BA.1 and BA.2, respectively. 12 (68%) patients had renal transplants. Only 36% of patients received three doses of COVID-19 vaccines. 23 (92%) patients required hospitalization. 20 (80%) patients survived and 6 (25%) required intensive care unit (ICU) admission. Among ICU patients, 66.7% were more than 50 years, 50% had two to three comorbidities and 5 out of 6 (83%) died. The mortality of transplant patients infected with Omicron variants in our cohort was higher than other centers as a limited number of patients received booster vaccines. Optimizing booster vaccination is the most efficient method to improve the mortality of COVID-19 in transplant recipients recognizing the inefficacy of monoclonal antibodies in the presence of SARS-CoV-2 emerging variants. We did not show a difference in mortality in transplant patients infected with Omicron BA.1 and BA.2 knowing the limitation of our sample size.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Transplant Recipients / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: J Epidemiol Glob Health Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Transplant Recipients / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: J Epidemiol Glob Health Year: 2023 Document Type: Article